Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)
Go back to Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 14.65 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.65 | 52 Week High | $117.12 | |||
| Open | $14.65 | 52 Week Low | $46.52 | |||
| Day High | $14.65 | P/E | N/A | |||
| Day Low | $14.65 | EPS | $-1.97 | |||
| Volume | 9,155 | |||||
